Ion Channel -Targeted Drug Development Summit

The ion channel field is gaining renewed momentum. Advances in cryo-EM, automated electrophysiology, and computational modelling are unlocking a historically complex target class, while recent clinical successes and increased biopharma investment are accelerating pipelines across CNS, cardiovascular, renal, and emerging indications. With new modalities entering the clinic and a growing understanding of channel biology, ion channel drug discovery is entering a critical phase of innovation and opportunity.

As the first industry-led, modality and indication-agnostic meeting, the Ion Channel-Targeted Drug Development Summit brings together leading innovators from across biopharma and academia, including Nocion Therapeutics, Maxion Therapeutics,Mair Therapeutics,Navega Therapeutics, Quiver Biosciences, GSK, Harvard Medical School, and Brown University, to share the latest advances in discovery, translational science, and clinical development.

Join ion channel-focused experts to exchange insights, build collaborations, and accelerate the next generation of therapeutics from discovery to clinic.


URLs:
Website: https://go.evvnt.com/3666421-0?pid=2874
Brochure: https://go.evvnt.com/3666421-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference Only: USD 3099.00,
Academic Pricing - Conference Only: USD 2699.00,
Service Provider Pricing - Conference Only: USD 3799.00

Speakers: Marc Rogers, Drug Discovery Consultant, Albion Drug Discovery Services Ltd, Michael Gendreau, Chief Medical Officer, Dogwood Therapeutics, Stephanie Tagliatela, Co-Founder and Chief Scientific Officer, Encoded Therapeutics, Johanna Marines, Head of Preclinical Development, Mabqi, Alexei Pushechnikov, Vice President MedChem, Mair Therapeutics, Edward Humphries, Director - Discovery Biology, Maxion Therapeutics, Alejandro Amador, Vice President of R and D and Operations, Navega Therapeutics, Jim Ellis, Chief Scientific Officer, Nocion Therapeutics, Inc., Jim Sahn, Co-Founder, NuvoNuro, Fabricio Simao, Senior Principal Scientist, Quiver Bioscience, Dan Elbaum, Chief Scientific Officer, QurAlis Corp., Rajesh Khanna, Chief Scientific Officer, Regulonix, LLC, Robin Loving, Chief Scientific Officer, Salipro Biotech AB, Stefan McDonough, Adjunct Professor of Brain Science, Brown University, Bruce Bean, Professor of Neurobiology, Harvard Medical School, Christopher Ahern, Professor of Molecular Physiology and Biophysics, The University of Iowa, Harley Kurata, Professor, University of Alberta, Theodore (Ted) Price, Professor, Director Center for Advanced Pain Studies, University of Texas at Dallas